Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma

Authors

Mansoor Saleh, Aga Khan UniversityFollow
M B. Khazaeli, University Of Alabama At Birmingham, USA
Richard Wheeler, University Of Alabama At Birmingham, USA
Edward Dropcho, University Of Alabama At Birmingham, USA
Tiepu Liu, University Of Alabama At Birmingham, USA
Marshall Urist, University Of Alabama At Birmingham, USA
Donald Miller, University Of Alabama At Birmingham, USA
Sharon Lawson, University Of Alabama At Birmingham, USA
Pam Dixon, University Of Alabama At Birmingham, USA
Charles Russell, University Of Alabama At Birmingham, USA

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

In a phase I trial, 12 patients with G_D2 antigen-positive metastatic melanoma received the murine anti-G_D2 monoclonal antibody 14G2a. The monoclonal antibody was administered in four doses over an 8-day period with total dose ranging from 10 to 120 mg. All patients receiving >10 mg of 14G2a experienced transient abdominal/pelvic pain during the antibody infusion. Five patients had a delayed extremity pain syndrome following the third and fourth antibody infusion. Four of the five patients developed neurological toxicity, including two patients with significant although reversible motor neuropathy. Two of the patients developed hyponatremia secondary to a syndrome of inappropriate antidiuretic hormone. All 12 patients developed high levels of human anti-14G2a antibody. The plasma half-life of 14G2a was 42 ± 6 (SD) h. One patient each had a partial response, mixed response, and stable disease, respectively. The very modest antitumor activity accompanied by dose-limiting neurological toxicity at total doses >80 mg may restrict the clinical utility of murine 14G2a.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Cancer research

Recommended Citation

Saleh, M., Khazaeli, M. B., Wheeler, R., Dropcho, E., Liu, T., Urist, M., Miller, D., Lawson, S., Dixon, P., Russell, C. (1992). Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer research, 52(16), 4342-4347.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/144